[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI1150678T1 - Uporaba inhibitorjev 3-hidroksi-3-metilglutaril koencim A reduktaze za izdelavo zdravila za zdravljenje diabeticne nevropatije - Google Patents

Uporaba inhibitorjev 3-hidroksi-3-metilglutaril koencim A reduktaze za izdelavo zdravila za zdravljenje diabeticne nevropatije

Info

Publication number
SI1150678T1
SI1150678T1 SI200030962T SI200030962T SI1150678T1 SI 1150678 T1 SI1150678 T1 SI 1150678T1 SI 200030962 T SI200030962 T SI 200030962T SI 200030962 T SI200030962 T SI 200030962T SI 1150678 T1 SI1150678 T1 SI 1150678T1
Authority
SI
Slovenia
Prior art keywords
coenzym
methylglutaryl
medicament
hydroxy
manufacture
Prior art date
Application number
SI200030962T
Other languages
English (en)
Inventor
Norman E Inst Med Sci Cameron
Mary A Inst Med Sci Dia Cotter
Original Assignee
Astrazeneca Ab
Univ Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9902594.2A external-priority patent/GB9902594D0/en
Priority claimed from GBGB9902591.8A external-priority patent/GB9902591D0/en
Application filed by Astrazeneca Ab, Univ Aberdeen filed Critical Astrazeneca Ab
Publication of SI1150678T1 publication Critical patent/SI1150678T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200030962T 1999-02-06 2000-02-01 Uporaba inhibitorjev 3-hidroksi-3-metilglutaril koencim A reduktaze za izdelavo zdravila za zdravljenje diabeticne nevropatije SI1150678T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9902594.2A GB9902594D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
GBGB9902591.8A GB9902591D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
PCT/GB2000/000280 WO2000045818A1 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
EP00901744A EP1150678B1 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy

Publications (1)

Publication Number Publication Date
SI1150678T1 true SI1150678T1 (sl) 2008-02-29

Family

ID=26315085

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200030962T SI1150678T1 (sl) 1999-02-06 2000-02-01 Uporaba inhibitorjev 3-hidroksi-3-metilglutaril koencim A reduktaze za izdelavo zdravila za zdravljenje diabeticne nevropatije
SI200031063T SI1897546T1 (sl) 1999-02-06 2000-02-01 Kombinirani sestavki, ki obsegajo (E)-7-(4-(4-fluorofenil)-6-izopropil-2 -(metil(metilsulfonil)amino)pirimidin-5-il)(3r,5s)-3,5-dihidroksihept-6- enojsko kislino

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200031063T SI1897546T1 (sl) 1999-02-06 2000-02-01 Kombinirani sestavki, ki obsegajo (E)-7-(4-(4-fluorofenil)-6-izopropil-2 -(metil(metilsulfonil)amino)pirimidin-5-il)(3r,5s)-3,5-dihidroksihept-6- enojsko kislino

Country Status (34)

Country Link
US (4) US6894058B1 (sl)
EP (2) EP1897546B1 (sl)
JP (3) JP2002536332A (sl)
KR (1) KR100699757B1 (sl)
CN (1) CN1196488C (sl)
AR (1) AR025512A1 (sl)
AT (2) ATE367162T1 (sl)
AU (1) AU763970B2 (sl)
BR (1) BR0007996A (sl)
CA (1) CA2368186C (sl)
CY (2) CY1106879T1 (sl)
CZ (2) CZ302881B6 (sl)
DE (2) DE60035575T2 (sl)
DK (2) DK1897546T3 (sl)
EE (2) EE05556B1 (sl)
ES (2) ES2286995T3 (sl)
GB (1) GB0001662D0 (sl)
HK (2) HK1041223A1 (sl)
HU (1) HU227642B1 (sl)
IL (3) IL144730A0 (sl)
IS (2) IS2793B (sl)
MX (1) MXPA01007821A (sl)
MY (1) MY138289A (sl)
NO (1) NO330400B1 (sl)
NZ (3) NZ525419A (sl)
PL (1) PL198098B1 (sl)
PT (2) PT1150678E (sl)
RU (1) RU2239456C2 (sl)
SI (2) SI1150678T1 (sl)
SK (2) SK287792B6 (sl)
TR (1) TR200102229T2 (sl)
TW (1) TWI230067B (sl)
WO (1) WO2000045818A1 (sl)
ZA (1) ZA200105885B (sl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
CA2399463A1 (en) * 2000-02-10 2001-08-16 Takeda Chemical Industries, Ltd. Combination drug
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
DE10025308A1 (de) * 2000-05-23 2001-11-29 Bayer Ag Kombination von Cerivastatin mit ACE Inhibitoren und ihre Verwendung in Arzneimitteln
AR030379A1 (es) * 2000-08-22 2003-08-20 Novartis Ag Combinaciones
PE20020617A1 (es) * 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
AU9422101A (en) * 2000-10-12 2002-04-22 Nissan Chemical Ind Ltd Preventives and remedies for complications of diabetes
EP1326591A2 (en) * 2000-10-18 2003-07-16 Pfizer Products Inc. Combination of statins and sorbitol dehydrogenase inhibitors
SK6092003A3 (en) 2000-11-30 2004-07-07 Pfizer Prod Inc Combination of GABA agonists and aldosereductase inhibitors
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
AU2003209851A1 (en) * 2002-03-20 2003-09-29 The University Of Queensland Method of treatment and/or prophylaxis
TW200305415A (en) * 2002-03-22 2003-11-01 Novartis Ag Combination of organic compounds
JP4395633B2 (ja) * 2002-08-29 2010-01-13 学校法人鈴鹿医療科学大学 非神経細胞の神経細胞への分化成熟法、該組成物と該組成物探索法
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
DE10302452B4 (de) * 2003-01-23 2005-02-24 Aventis Pharma Deutschland Gmbh Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
JP2005232151A (ja) * 2003-04-28 2005-09-02 Iichiro Shimomura 糖取り込み能増強剤
US9345671B2 (en) 2003-04-28 2016-05-24 Daiichi Sankyo Company, Limited Adiponectin production enhancer
US7772272B2 (en) 2003-04-28 2010-08-10 Daiichi Sankyo Company, Limited Method for enhancing glucose uptake into warm-blooded animal adipocytes
WO2004112788A1 (en) * 2003-06-20 2004-12-29 Biostratum, Inc. Pyridoxamine for the treatment of diabetic kidney disease
US20090082407A1 (en) * 2004-06-18 2009-03-26 Biostratum, Inc. Pyridoxamine for the Treatment of Diabetic Kidney Disease
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
AU2003269484A1 (en) * 2003-09-11 2005-03-29 Biocon Limited Salt of atorvastatin with metformin
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005033067A1 (en) * 2003-10-07 2005-04-14 Biocon Limited SALT OF 1,2,6,7,8,8A-HEXAHYDRO-β,δ,6-TRIHYDROXY-2-METHYL-8-[(2S)-2-METHYL-1-OXOBUTOXY]-, (βR,δ R,1S,2S,6S,8S,8AR)- 1-NAPHTHALENEHEPTANOIC ACID WITH N,N-DIMETHYL-IMIDODICARBONIMIDIC DIAMIDE
KR100715114B1 (ko) * 2005-02-19 2007-05-10 한국유나이티드제약 주식회사 당뇨병 치료를 위한 약학적 조성물
CN101632673B (zh) * 2008-07-24 2011-08-10 鲁南制药集团股份有限公司 含有氯沙坦、吡格列酮和瑞舒伐他汀的药物组合物及其新用途
SI2326632T1 (sl) 2008-09-06 2017-11-30 Bionevia Pharmaceuticals, Inc. Nov kokristal holin epalrestata
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2013072770A2 (en) 2011-11-15 2013-05-23 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising atorvastatin and glimepiride
WO2015053589A1 (ko) * 2013-10-11 2015-04-16 가톨릭대학교 산학협력단 메트포민 및 스타틴의 복합제를 이용한 자가면역질환의 예방 또는 치료용 조성물
KR101579656B1 (ko) * 2013-12-12 2015-12-22 가천대학교 산학협력단 프라바스타틴과 발사르탄을 포함하는 약학 조성물
CN110747206B (zh) * 2019-11-05 2021-11-23 昆明理工大学 3-羟基-3-甲基戊二酸单酰辅酶a还原酶基因rkhmgr及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5190970A (en) 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
DK0636027T3 (da) 1992-04-13 2000-01-31 Zeneca Ltd Angiotensin-II-antogonister mod sygdomme forbundet med forringet neuronal ledningshastighed, især diabetisk neuropati
GB9208116D0 (en) * 1992-04-13 1992-05-27 Ici Plc Therapeutic agents
WO1995013063A1 (en) 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
EP0754042A4 (en) 1994-03-29 2004-06-23 Merck & Co Inc TREATING ATHEROSCLEROSIS WITH IMIDAZOLES BLOCKING THE ANGIOTENSIN II RECEPTOR
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
AU713277B2 (en) 1996-04-05 1999-11-25 Takeda Pharmaceutical Company Limited Pharmaceutical combination containing a compound having angiotensin II and antagonistic activity
GB9714274D0 (en) * 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6262076B1 (en) * 2000-01-28 2001-07-17 Ajinomoto Co., Inc. Pharmaceutical composition for use in the treatment of diabetic neuropathy
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment

Also Published As

Publication number Publication date
CY1106879T1 (el) 2012-05-23
HUP0105138A2 (hu) 2002-04-29
CY1110992T1 (el) 2015-06-11
NZ525419A (en) 2004-12-24
AR025512A1 (es) 2002-12-04
NZ536433A (en) 2006-08-31
NO20013812L (no) 2001-10-02
IL144730A0 (en) 2002-06-30
SK287792B6 (sk) 2011-10-04
MY138289A (en) 2009-05-29
HUP0105138A3 (en) 2002-11-28
ATE367162T1 (de) 2007-08-15
KR20010089635A (ko) 2001-10-06
AU763970B2 (en) 2003-08-07
CN1196488C (zh) 2005-04-13
ES2352803T3 (es) 2011-02-23
CN1338937A (zh) 2002-03-06
PL350312A1 (en) 2002-12-02
EP1150678A1 (en) 2001-11-07
HU227642B1 (en) 2011-10-28
EP1897546B1 (en) 2010-10-27
EE200100405A (et) 2002-10-15
DE60035575T2 (de) 2008-04-03
JP2012051898A (ja) 2012-03-15
HK1118209A1 (en) 2009-02-06
WO2000045818A1 (en) 2000-08-10
TR200102229T2 (tr) 2001-12-21
US20050209128A1 (en) 2005-09-22
ES2286995T3 (es) 2007-12-16
US20120041010A1 (en) 2012-02-16
CZ302881B6 (cs) 2012-01-04
CZ302893B6 (cs) 2012-01-11
PL198098B1 (pl) 2008-05-30
DK1897546T3 (da) 2011-01-17
DE60035575D1 (de) 2007-08-30
EE05556B1 (et) 2012-08-15
NZ513061A (en) 2003-06-30
NO20013812D0 (no) 2001-08-03
US20090186908A1 (en) 2009-07-23
HK1041223A1 (en) 2002-07-05
SK286854B6 (sk) 2009-06-05
EP1897546A1 (en) 2008-03-12
SK11102001A3 (sk) 2002-05-09
IS8978A (is) 2011-08-23
DK1150678T3 (da) 2007-10-08
PT1897546E (pt) 2010-12-15
GB0001662D0 (en) 2000-03-15
ATE485823T1 (de) 2010-11-15
PT1150678E (pt) 2007-09-14
BR0007996A (pt) 2001-10-30
MXPA01007821A (es) 2004-08-19
JP2014065718A (ja) 2014-04-17
SI1897546T1 (sl) 2011-02-28
DE60045168D1 (de) 2010-12-09
RU2239456C2 (ru) 2004-11-10
CA2368186A1 (en) 2000-08-10
AU2304700A (en) 2000-08-25
CZ20012806A3 (cs) 2002-02-13
IL208330A0 (en) 2010-12-30
KR100699757B1 (ko) 2007-03-27
TWI230067B (en) 2005-04-01
EP1150678B1 (en) 2007-07-18
IS2820B (is) 2012-12-15
IL144730A (en) 2010-12-30
CA2368186C (en) 2008-06-03
IS6016A (is) 2001-07-20
EE05621B1 (et) 2013-02-15
NO330400B1 (no) 2011-04-04
JP2002536332A (ja) 2002-10-29
EE201200015A (et) 2012-10-15
ZA200105885B (en) 2002-10-17
US6894058B1 (en) 2005-05-17
IS2793B (is) 2012-08-15

Similar Documents

Publication Publication Date Title
HUP0105138A3 (en) Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
AU2180400A (en) A pharmaceutical combination for the treatment of depression
HUP0200556A3 (en) Medicament for treating diabetes
AUPP609198A0 (en) Use of non-peptidyl compounds for the treatment of insulin related ailments
AU5760900A (en) Multiple agent diabetes therapy
IL147790A0 (en) Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity
HU0103987D0 (en) New compounds with pharmaceutical activity
AU2003279442A1 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
AU2000276362A1 (en) Composition for the treatment of diabetes
AU7622000A (en) Compounds for the treatment of viral-mediated diseases
AU7327101A (en) A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
GB9907571D0 (en) Compounds
AU4477700A (en) Licensed band adaptations
AU7309900A (en) Anti-irritant disposable diaper
EP1213021A4 (en) MEDICINE AGAINST DIABETES
AU2432001A (en) Treatment of mental conditions including depression
IL162853A0 (en) The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus
AU7982098A (en) Use of beta2-adrenoceptor agonists for the manufacture of a medicament for the treatment of scoliosis
AU2003291368A1 (en) Compounds for the treatment of tobacco dependence and withdrawal
AU3071799A (en) Use of pkc inhibitors for the manufacture of a medicament for the treatment of cytomegalovirus infection
AU3071999A (en) Use of pkc inhibitors for the manufacture of a medicament for the treatment of autoimmune diseases
AU3071899A (en) Use of pkc-inhibitors for the manufacture of a medicament for the treatment of asthma
GB0212790D0 (en) Medicament for the treatment of diabetes
EP1197225A4 (en) AGENTS FOR DISEASES CAUSED BY PTH OR PTHrH
AU1271801A (en) Use of (r)-zacopride or a salt thereof for the manufacture of a medicament for the treatment of sleep apnea